GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT

• Status: Completed
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

Purpose:The aim of this project is to prospectively determine whether a single dose of GnRH-agonist administered at the time of implantation increases or not the reproductive outcome in patients undergoing in vitro fertilization ( IVF)/ intracytoplasmatic sperm injection(ICSI) triggered by a GnRH-agonist followed by a small bolus of human chorionic gonadotropin (hCG 1500 IU) the day of oocyte retrieval.

Acronyms:

GnRH: gonadotropin-releasing hormone FSH: follicle stimulating hormone LH: luteinizing hormone HCG:human chorionic gonadotropin IVF:In vitro fertilization ICSI:intracytoplasmatic sperm injection OHSS:ovarian hyperstimulation syndrome OMEGA: oocyte maturation employing GnRH-agonist OPU: ovum pick up NaCl: sodium chloride

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire Ibn Rochd
• Treatments: Deslorelin; Pharmaceutical Solutions; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• Female age < 40 years

• Baseline FSH and LH < 12 IU/l.

• Body Mass Index > 18 and < 35 kg/m2

• No uterine (fibroids, mullerian malformations), ovarian ( endometrioma) or adnexa (hydrosalpinx) abnormalities

• Patients with at least one embryo at transfer time

Exclusion Criteria:

• Very high risk of OHSS (> 30 follicles > 12 mm the day of ovulation triggering).

• Reduced ovarian reserve

• Fertilization failure

• Severe endocrinopathy

• Azoospermia